Market Overview

UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

Related NPSP
NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH)
NPS Pharma's Natpara Likely To Be Reviewed In September - Analyst Blog

In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Buy to Hold, but reiterated the $38.00 price target.

In the report, Jefferies noted, “FY14 guidance/4Q13 sales of Gattex preannounced on 1/8/14. Solid Gattex U.S. launch in 2013 and anticipation of bigger Natpara opportunity resulted in strong stock performance. Now trading at ~17.2x EV/'14 revenue (vs. ~16.1x for BMRN and ~17.5x for ALXN), we view near term, potential of Gattex/Revestive and Natpara is largely priced in. Thus, we downgrade NPSP to Hold on valuation and maintain $38 PT.”

NPS Pharmaceuticals closed on Tuesday at $37.95.

Posted-In: Eun K. Yang JefferiesAnalyst Color Downgrades Analyst Ratings

 

Most Popular

Related Articles (NPSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters